|Bid||18.40 x 1000|
|Ask||19.20 x 800|
|Day's range||18.22 - 19.23|
|52-week range||12.52 - 38.80|
|Beta (5Y monthly)||1.12|
|PE ratio (TTM)||2.66|
|Earnings date||25 July 2022 - 29 July 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||52.35|
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.
Bar Chart Bar Chart ~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-130 ~ ~ Neurofilament Light Chain (NfL) in CSF near baseline at 12 months in patients treated with AMT-130 ~ ~ Biomarker and clinical data including 24-month follow-up in the low-dose U.S. cohort a